69881-27-2

Upstream product

• 69684-83-9 (+/-)-sorbinil 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 79791-46-1 (S)-4-cyano-2,3-dihydro-6-fluoro-4-<(S)-(1-phenylethyl)amino>-4H-1-benzopyran 
• 590-28-3 potassium cyanate 
• 103834-11-3 (S)-4-amino-6-fluoro-chromane-4-carboxylic acid 
• 371-41-5 4-Fluorophenol 
• 103196-96-9 C₁₂H₁₀FNO₃ 
• 79791-44-9 (S)-2,3-dihydro-6-fluoro-4-<(1-phenylethyl)imino>-4H-1-benzopyran 
• 82799-12-0 (S)-1'-chloro-6-fluoro-2,3-dihydro-5'-imino-3'-<(S)-1-phenylethyl>spiro<4H-1-benzopyran-4,4'-imidazolidin>-2'-one hydrochloride 
• 103197-13-3 (S)-methyl 4-amino-6-fluorochroman-4-carboxylate 
• 103197-09-7 4-amino-2,3-dihydro-6-fluoro-4H-1-benzopyran-4-carboxylic acid, hydrochloride 
• 103197-05-3 N-acetyl-2-(2-bromoethoxy)-5-fluorophenylglycine 
• 103197-08-6 4-acetamido-2,3-dihydro-6-fluoro-4H-1-benzopyran-4-carboxylic acid 
• 332-48-9 2-(4-fluorophenoxy)-ethylbromide 

Relevant academic research and scientific papers

Substituted spiro-2',4'-diones as aldose reductase inhibitors

Aldose reductase (EC 1.1.1.21) is believed to be involved in the pathogenesis of diabetic complications.Inhibitors of this enzyme could be useful for the treatment of diabetic cataracts and neuropathies.A series of spiro-2',4'-d

USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS

The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R 4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula

General and practical catalytic enantioselective Strecker reaction of ketoimines: Significant improvement through catalyst tuning by protic additives

Significant improvement in enantioselectivity and catalyst activity was achieved for the catalytic enantioselective Strecker reaction. Using a catalyst (1-2.5mol%) prepared from Gd(OiPr)3 and D-glucose derived ligand 1, and in the pr

Lipase-catalyzed resolution of 5,5-disubstituted hydantoins

Chiral non-racemic 5,5-disubstituted hydantoins were prepared by lipase-catalyzed enantioselective hydrolyses of their N-acyloxymethyl groups or esterification of their N-hydroxymethyl groups.

Process for the production of asymmetric hydantoins

An improved process for preparing (4S)-6-fluorospiro-[chroman-4,4''-imidazolidine]-2'',5''-dione (sorbinil) or its (2R)-methyl derivative (2-methylsorbinil) is disclosed herein, starting from p-fluorophenol in each instance. The final products obtained ha

S-6-fluoro-4-aminochroman-4-carboxylic acid derivatives useful as intermediates for sorbinil

Chiral sorbinil intermediates of the formula STR1 wherein R is hydrogen or benzyloxycarbonyl and Y is hydroxy or amino, processes therefor, and processes for the conversion thereof to sorbinil.

Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid

6-Fluoro-4-chromanone can be regenerated from (R)-6-fluoro-4-ureidochroman-4-carboxylic acid, or from mixtures of (R)-6-fluoro-4-ureidochroman-4-carboxylic acid and its racemic modification, by oxidation with a permanganate, especially potassium permanganate. 6-Fluoro-4-chromanone is a chemical intermediate useful for preparing sorbinil, an aldose reductase inhibitor which can be used in clinical medicine for the control of the chronic complications of diabetes. (R)-6-Fluoro-4-ureidochroman-4-carboxylic acid and its racemic modification are by-products from the production of sorbinil from 6-fluoro-4-chromanone.

Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil

6-Fluoro-4-chromanone, a sorbinil intermediate, is regenerated from enantiomeric and mixtures of enantiomeric and racemic compounds obtained as major by-products in the synthesis of sorbinil. The regenerated intermediate is useful in the synthesis of additional sorbinil.